GlaxoSmithKline News and Research

RSS

biocrea and Pfizer jointly presented details on novel PDE10 inhibitors

biocrea, a biopharmaceutical company focusing on novel treatments for disorders of the central nervous system (CNS), today reported details on the design and synthesis of novel, brain-penetrating phosphodiesterase-10 (PDE10) inhibitors developed in collaboration with Pfizer Inc. (NYSE: PFE). The data were featured in joint presentations1 with Pfizer at the recent 241st ACS National Meeting & Exposition, an event organized by the American Chemical Society (ACS).

10 May 2011

Unigene first quarter net loss decreases 58% to $6.6 million

Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced first quarter financial results for the period ended March 31, 2011. The Company highlighted significant progress achieved in the first quarter with the execution of its turnaround strategy.

9 May 2011

POZEN reports revenue of $4.5 million for first quarter 2011

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced results for the first quarter ended March 31, 2011.

5 May 2011

Anacor first quarter revenues increase to $2.2 million

Anacor Pharmaceuticals reviewed today its first quarter accomplishments and reported financial results for the quarter ended March 31, 2011.

5 May 2011

Astex earns GBP5.9 M milestone payment from GSK for fragment-based screening platform

Astex Therapeutics, the UK-based biotechnology company developing targeted therapies for oncology and virology, announced that it has achieved multiple early milestones in its fragment-based drug discovery collaboration with GlaxoSmithKline which commenced in November 2009.

3 May 2011

Regulatory Science Consortium adds 10 new member organizations

Critical Path Institute is proud to announce that the Regulatory Science Consortium, an arm of the Critical Path to TB Drug Regimens, has added 10 new member organizations that include over 100 participants in five workgroups.

30 Apr 2011

Enrollment complete in Unigene's oral PTH Phase 2 osteoporosis study in postmenopausal women

Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today that the Company has completed patient enrollment of its Phase 2 study with an experimental oral parathyroid hormone (PTH) analog for the treatment of osteoporosis in postmenopausal women.

28 Apr 2011

GSK receives FDA approval for Lamictal XR to treat partial seizures

GlaxoSmithKline announced today that the U.S. Food and Drug Administration has approved Lamictal XR Extended-Release Tablets for conversion to monotherapy in patients 13 years and older with partial seizures taking one anti-epileptic drug.

26 Apr 2011

FiberChoice launches 'Choices for Better Health' nationwide sweepstakes

FiberChoice® chewable fiber supplements today launched the "Choices for Better Health" nationwide sweepstakes to support the simple ways that Americans can defend their health each day. The 28-day campaign lives on Twitter and encourages people to share the small, smart choices they make for overall health and wellness.

22 Apr 2011

ARIAD executes three exclusive out-license agreements for ARGENT cell-signaling regulation technology

ARIAD Pharmaceuticals, Inc. today announced execution of three exclusive out-license agreements for separate aspects of its ARGENT™ cell-signaling regulation technology.

20 Apr 2011

Bedford Labs launches cancer drug Topotecan Hydrochloride for Injection

Bedford Laboratories, a division of Ben Venue Laboratories, Inc., is pleased to announce the addition of Topotecan Hydrochloride for Injection, 4 mg (base)/vial to its diverse portfolio. Topotecan is AP Bioequivalent to the reference listed drug Hycamtin® (topotecan HCl) for injection by GlaxoSmithKline.

19 Apr 2011

U.S. District Court grants preliminary injunction to POZEN's Treximet patent lawsuit

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, announced today that the U.S. District Court for the Eastern District of Texas has granted a preliminary injunction ordering Par Pharmaceutical Inc. not to make, use, sell, offer to sell, or import into the United States a generic version of sumatriptan/naproxen sodium that competes with Treximet sold by GlaxoSmithKline in the United States under an exclusive license from the Company.

15 Apr 2011

GSK announces safety profile of orlistat and alli

GlaxoSmithKline (GSK) is committed to ensuring that consumers and physicians understand the safety profile of orlistat and alli. alli is safe and effective when used as directed. Orlistat is minimally absorbed in the blood and works locally in the gastro-intestinal tract. GSK continues to proactively monitor for the safety of orlistat and share all relevant information with regulatory agencies.

15 Apr 2011

Consumer group calls for ban on weight loss drugs Alli and Xenical

According to the consumer watchdog Public Citizen, the weight loss drugs Alli and Xenical should be removed from the market because of the growing risk of side effects that include liver damage, pancreatitis and kidney stones.

15 Apr 2011

Marking World Health Day, WHO warns misuse of antibiotics undermining global fight against infectious diseases

U.N. officials on Thursday marked World Health Day with a warning that "the misuse and irrational use of antibiotics has undermined the global fight against tuberculosis and malaria, warning of a possible return to the days before the drugs were developed," and called for urgent action to control the spread of drug resistance, Reuters reports.

8 Apr 2011

Lecture to explain science behind modern pharmaceutical products

The science behind the creation of medicines is the subject of a lecture at the University of Greenwich's Medway Campus on Wednesday, April 13.

8 Apr 2011

Strathclyde establishes new EPSRC Centre to improve chemical manufacturing

An EPSRC Centre for revolutionising the way pharmaceuticals and other chemicals are made is being officially launched today.

8 Apr 2011

GlaxoSmithKline, XenoPort receive FDA approval for Horizant to treat RLS

On April 6, the U.S. Food and Drug Administration approved Horizant Extended Release Tablets, a once-daily treatment for moderate-to-severe restless legs syndrome.

8 Apr 2011

FDA approves Horizant Extended-Release Tablets for Restless Legs Syndrome

GlaxoSmithKline and XenoPort, Inc. announced Wednesday that the U.S. Food and Drug Administration (FDA) has approved Horizant™ (gabapentin enacarbil) Extended-Release Tablets for the treatment of moderate-to-severe primary Restless Legs Syndrome in adults. Horizant is not recommended for patients who are required to sleep during the daytime and remain awake at night.

7 Apr 2011

Ascletis raises $100 million in committed financing

Ascletis, Inc., a U.S.-China specialty life sciences venture focused on cancer and infectious disease therapeutics, today announced the company's formation and completion of a Series A private equity financing. Ascletis has raised US$100 million in committed financing including a first tranche of US$50 million. The investors, led by Hangzhou Binjiang Investment Holding Co., Ltd., included private entrepreneurs from China and other countries including the United States.

6 Apr 2011